42,162 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Advisors Preferred LLC

Advisors Preferred LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 42,162 shares of the biopharmaceutical company's stock, valued at approximately $2,024,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Financial Advocates Investment Management purchased a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $478,000. State of Alaska Department of Revenue lifted its holdings in Halozyme Therapeutics by 213.4% during the 4th quarter. State of Alaska Department of Revenue now owns 46,508 shares of the biopharmaceutical company's stock worth $2,222,000 after buying an additional 31,670 shares in the last quarter. Verity Asset Management Inc. boosted its position in Halozyme Therapeutics by 19.3% in the 4th quarter. Verity Asset Management Inc. now owns 45,616 shares of the biopharmaceutical company's stock valued at $2,181,000 after buying an additional 7,368 shares during the period. Tempus Wealth Planning LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth $265,000. Finally, abrdn plc purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth $6,152,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

HALO has been the subject of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $60.89.

Insider Buying and Selling

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares of the company's stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Stock Performance

HALO traded up $0.78 during trading hours on Wednesday, hitting $58.11. 888,165 shares of the stock were exchanged, compared to its average volume of 1,286,692. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock has a 50-day simple moving average of $52.09 and a 200-day simple moving average of $54.45. The stock has a market cap of $7.39 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 12 month low of $34.36 and a 12 month high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.